Mass spectrometric and functional aspects of drug–protein conjugation

A Tailor, JC Waddington, X Meng… - Chemical research in …, 2016 - ACS Publications
The covalent binding of drugs (metabolites) to proteins to form drug–protein adducts can
have an adverse effect on the body. These adducts are thought to be responsible for …

Separation and detection methods for covalent drug–protein adducts

S Zhou - Journal of Chromatography B, 2003 - Elsevier
Covalent binding of reactive metabolites of drugs to proteins has been a predominant
hypothesis for the mechanism of toxicity caused by numerous drugs. The development of …

Drug–protein adducts: past, present, and future

TA Baillie - Medicinal Chemistry Research, 2020 - Springer
Research over the past half-century has demonstrated that the metabolism of drugs and
other foreign compounds to chemically reactive intermediates that bind covalently to …

Mass spectrometry approaches to monitor protein–drug interactions

N Zinn, C Hopf, G Drewes, M Bantscheff - Methods, 2012 - Elsevier
Recent advances in mass spectrometry-based approaches have enabled the investigation
of drug–protein interactions in various ways including the direct detection of drug–target …

Proteomics in immunological reactions to drugs

A Ariza, MI Montañez, D Perez-Sala - Current opinion in allergy …, 2011 - journals.lww.com
Immunological reactions to drugs pose important clinical problems. Since early works
exploring drug–protein interactions, there has been steady progress in this field. However …

Drug− protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development

DC Evans, AP Watt, DA Nicoll-Griffith… - Chemical research in …, 2004 - ACS Publications
It is generally accepted that there is neither a well-defined nor a consistent link between the
formation of drug− protein adducts and organ toxicity. Because the potential does exist …

Identification and quantification of drug–albumin adducts in serum samples from a drug exposure study in mice

L Switzar, LM Kwast, H Lingeman, M Giera… - … of Chromatography B, 2013 - Elsevier
The formation of drug–protein adducts following the bioactivation of drugs to reactive
metabolites has been linked to adverse drug reactions (ADRs) and is a major complication …

Advances in mass spectrometry-based epitope mapping of protein therapeutics

XR Liu, RYC Huang, F Zhao, G Chen, L Tao - Journal of pharmaceutical …, 2022 - Elsevier
Monoclonal antibody (mAb) has grown to be the major asset in protein therapeutics market
since its initial introduction in 1980s. To identify a suitable mAb as a drug candidate for …

Revealing promiscuous drug–target interactions by chemical proteomics

M Bantscheff, A Scholten, AJR Heck - Drug discovery today, 2009 - Elsevier
The (poly-) pharmacological activities of a drug can only be understood if its interactions with
cellular components are comprehensively characterized. Mass spectrometry-based …

Drug bioactivation covalent binding to target proteins and toxicity relevance

S Zhou, E Chan, W Duan, M Huang… - Drug metabolism …, 2005 - Taylor & Francis
A number of therapeutic drugs with different structures and mechanisms of action have been
reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes …